Impact of temozolomide on immune response during malignant glioma chemotherapy - Wikidata - wikimedia - TriplyDB

Impact of temozolomide on immune response during malignant glioma chemotherapy

Impact of temozolomide on immune response during malignant glioma chemotherapy

http://www.wikidata.org/entity/Q36362798

about

Micheliolide derivative DMAMCL inhibits glioma cell growth in vitro and in vivo Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity Single vs. combination immunotherapeutic strategies for glioma.Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy.Nanotube x-ray for cancer therapy: a compact microbeam radiation therapy system for brain tumor treatment.Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas.MGMT testing allows for personalised therapy in the temozolomide era.Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.The multidrug-resistance transporter Abcc3 protects NK cells from chemotherapy in a murine model of malignant glioma.Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models.PinX1-siRNA/mPEG-PEI-SPION combined with doxorubicin enhances the inhibition of glioma growth CNS macrophages and peripheral myeloid cells in brain tumours.Hypoxic and Reoxygenated Microenvironment: Stemness and Differentiation State in Glioblastoma.Temozolomide-loaded PLGA nanoparticles to treat glioblastoma cells: a biophysical and cell culture evaluation.mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells.Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment Covalent nano delivery systems for selective imaging and treatment of brain tumors.Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433).MiR-29b inhibits the growth of glioma via MYCN dependent way ALKBH7 drives a tissue and sex-specific necrotic cell death response following alkylation-induced damage.Anti-SSTR2 peptide based targeted delivery of potent PLGA encapsulated 3,3'-diindolylmethane nanoparticles through blood brain barrier prevents glioma progression.Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme.Immunotherapy for Pediatric Brain Tumors.Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma.Rational Design of Ruthenium Complexes Containing 2,6-Bis(benzimidazolyl)pyridine Derivatives with Radiosensitization Activity by Enhancing p53 Activation.Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma.Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors.Generation of a PAX6 knockout glioblastoma cell line with changes in cell cycle distribution and sensitivity to oxidative stress.In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment.FoxM1-mediated RFC5 expression promotes temozolomide resistance.CDK5 Inhibition Resolves PKA/cAMP-Independent Activation of CREB1 Signaling in Glioma Stem Cells.Challenges in cerebrospinal fluid shunting in patients with glioblastoma.Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma

P2860

Q28543364-A955C622-374C-4907-A6F2-EE28284EBCB0 Q28550138-46AAFBF1-12B7-4D6B-B594-847E8C81E3DF Q33668084-88EEB987-2621-48D0-BCF3-0166434F6A2C Q33670728-581FADBE-56EB-49B9-B6B4-985E0E0885D5 Q33746041-05B645B0-99CA-4403-9AF2-9D6EC3CB6258 Q34177641-D181391F-41BF-4418-9B65-C665F9764BAD Q34662481-03C611C6-989D-4A06-BFB5-2ACB6307B60A Q35507524-1376D6EA-AA40-4F39-9043-147897D6BE67 Q35827916-DF2D5B2F-AD86-40C4-A10A-D742912AD274 Q35909751-98DCE5EB-3A37-43D8-9562-6A0B378C9E3C Q36145632-F7F7B895-82E5-49B3-9B94-E0EE68555F71 Q36918102-180A2033-A11F-460B-BDD9-F09BF62EC0D3 Q37012579-6542EC95-B5B7-40D0-A7E1-B3C707206EBC Q37647868-0969CD68-ADEB-453C-8FEF-D6895A08EDD2 Q37710054-31F0A11E-FEED-41D1-9857-C771193118AD Q38203815-C162D1BC-715D-411B-8EEC-FA4BAFD2417A Q38742113-7B2DA82B-E7F4-4C67-9627-404AC8797793 Q38791773-1FB043C9-94B8-4AE2-B652-D6C346A00DBB Q38987085-9BB8F246-713A-4BE3-8CCC-210F8A372535 Q39152200-C01C6645-6B6E-498E-A388-A2786A2417F2 Q39367664-3AADE07D-34E6-4A5A-84E8-9599F28DA2E7 Q41141280-6A719928-3217-4490-AAA0-5847810C63FA Q41233255-4E4CEA92-52AD-4392-8370-2260ABED9279 Q41335643-8492B3CF-5751-40E6-8952-F0E5E89A50FF Q42371532-5AAE09A9-5B85-4A30-AA72-F270A1CD42DD Q43225522-9620AE41-63E1-421C-B8CC-C7DCEBB41295 Q46407536-E3272BC3-BAE0-408C-B82D-098026783AAB Q46586294-AC6A55EA-4B6D-44BC-BF18-EE1101C3B918 Q46737262-BC9C2EC0-98D4-41BB-BE30-FBBA35B3C2E3 Q47773621-DBCCCB17-9480-48D8-B7A6-930CC2157C13 Q48503168-34B948EE-1247-4233-AEAA-DC85AB9D2474 Q52715022-BDD00C96-25A3-4C2C-8883-9B36BF18AF97 Q52780147-1F93E3E0-B00A-4EBD-9E61-41D6D2791549 Q53726087-46666975-290B-431A-BDED-C42CB1B91EAA Q55010335-A4CDE57B-FA35-4DC2-BA45-0F3D69B3D225 Q55174270-5CA20D7F-1F90-4F98-97AD-88EDBFB51868 Q58693796-6A242DB4-1899-4182-A419-BF875B12F02D

P2860

Impact of temozolomide on immune response during malignant glioma chemotherapy

http://www.wikidata.org/entity/Q36362798

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Impact of temozolomide on immune response during malignant glioma chemotherapy

@ast

Impact of temozolomide on immune response during malignant glioma chemotherapy

@en

type

label

Impact of temozolomide on immune response during malignant glioma chemotherapy

@ast

Impact of temozolomide on immune response during malignant glioma chemotherapy

@en

prefLabel

Impact of temozolomide on immune response during malignant glioma chemotherapy

@ast

Impact of temozolomide on immune response during malignant glioma chemotherapy

@en

P1433

Q36362798-CAB279B7-335C-4490-93EB-9C6D0BE30AE7

P1476

Q36362798-68E9E589-89A8-4BB0-B01C-0327DC3B9D7E

P2093

Q36362798-06717250-5864-4577-A8B5-646399DF0A34

Q36362798-0CC5D196-FC92-4E55-A523-57BD64F69A42

Q36362798-AAFB140A-FCC6-40FB-86AC-DE209528D63B

Q36362798-EDCBEC3D-F7BF-47A9-A3C4-D3FF2E5BF87E

P275

Q36362798-07CB36CE-806A-40C7-B2ED-420B494FBF00

P2860

Q36362798-079578F8-54A3-4B0B-A94B-D7D6FB5D6336

Q36362798-15074DB7-C6AB-44A9-82DB-730544AB04E7

Q36362798-16A09FCB-2546-4744-AB9D-1442C1D4D6DC

Q36362798-17806712-C657-435F-B967-772A7F5DC957

Q36362798-1A73CE07-CB2E-4390-A267-B3A895BC5A76

Q36362798-1A8817EB-A681-453D-9877-F3E277610C9E

Q36362798-1C2D8CB5-089C-4B00-BD73-F6FE34756A47

Q36362798-1F8AFD19-16C7-41FB-BE89-5540B6C53BB8

Q36362798-24CEF406-0562-4A41-B48E-FD783E8860FC

Q36362798-2573BC64-3E72-4A08-9AD2-BD52EBE5EF2B

P304

Q36362798-17C777EC-1724-4264-9542-E5F5A9A8642F

P31

Q36362798-05EF25C4-0670-45FA-8F53-FB3A48F5A73B

Q36362798-8E7200A9-71F4-41FD-9B7D-07BD4B1070D5

P356

Q36362798-BB08C7B9-83DB-4FEA-83B8-3DA328BFA7AD

P478

Q36362798-276A96F5-B0D4-484F-A9AF-793296E92C49

P5008

Q36362798-1FB1AC6C-C2EE-4798-9FAB-B14A11683789

P577

Q36362798-6F6B7EE3-C0F5-4897-B476-CAAE6C58D96A

P5875

Q36362798-F750A448-58A5-47ED-B0EB-E29AB6290289

P698

Q36362798-E731676D-C82D-46CC-A87E-12581287BF46

P921

Q36362798-05C0E3B6-08A7-44AD-93B2-B3883CFD4E45

Q36362798-0820ABC8-F4C1-44C0-B6F7-58C800C4A60C

Q36362798-2D0A7937-1B44-4CE2-8BF2-3FD6E2992F28

Q36362798-BAB7E8E3-3F18-43EA-B2CA-CB8D347CD53F

Q36362798-EC15CDEB-1201-46C0-B1E8-7ABE87DC0D6B

P932

Q36362798-510F67CA-33AE-48B9-AAFC-E75560C11093

P356

P1433

Clinical and Developmental Immunology

P1476

Impact of temozolomide on immune response during malignant glioma chemotherapy

@en

P2093

Caroline Frishman

http://www.w3.org/2001/XMLSchema#string

Jaclyn Marrinan

http://www.w3.org/2001/XMLSchema#string

Prakash Sampath

http://www.w3.org/2001/XMLSchema#string

Sadhak Sengupta

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

A phase II study of extended low-dose temozolomide in recurrent malignant gliomas

Human monocytes undergo excessive apoptosis following temozolomide activating the ATM/ATR pathway while dendritic cells and macrophages are resistant

A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project.

Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector.

P304

831090

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/831090

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2012-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232974922

http://www.w3.org/2001/XMLSchema#string

P698

23133490

http://www.w3.org/2001/XMLSchema#string

P921

P932

3486128

http://www.w3.org/2001/XMLSchema#string